Alnylam second quarter revenue decreases to $20 which tadalafil is better .6 million Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, reported its consolidated financial results for the second quarter 2011 today, and company highlights. Alnylam remains concentrated and committed to the advancement of RNAi therapeutics all together new class of innovative medicines. Our progress in the first half of 2011 is certainly exemplified by the continuing advancement of our scientific pipeline. In this regard, we believe we’ve achieved important objectives lately with both our ‘Alnylam 5×15’ programs and also our partner-based applications, stated John Maraganore, Ph.D., CEO of Alnylam.
Columbia Laboratories second one fourth total net revenues decrease to $8.2 million Columbia Laboratories, Inc. Highlights of the next quarter include: Net product revenues had been $7.4 million in the second quarter of 2012, compared to $4.9 million in the second quarter of 2011, due to higher product sales to Merck Serono S.A. and Watson Pharmaceuticals, Inc. . Gross income on net item revenues remained the same at 39 percent compared with the second quarter of 2011. Operating income was $1.7 million in the second quarter of 2012 as operating expenses were down 31 percent from prior year levels.